These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 11403367

  • 1. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
    Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Ohman KP, Osbakken MD, Ostergern J.
    J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
    [Abstract] [Full Text] [Related]

  • 2. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D, Malmqvist K, Held C, Kahan T.
    J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
    [Abstract] [Full Text] [Related]

  • 3. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K, Kahan T, Edner M, Bergfeldt L.
    Am J Cardiol; 2002 Nov 15; 90(10):1107-12. PubMed ID: 12423712
    [Abstract] [Full Text] [Related]

  • 4. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M.
    Am J Hypertens; 2006 Sep 15; 19(9):927-36. PubMed ID: 16942935
    [Abstract] [Full Text] [Related]

  • 5. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L.
    J Hypertens; 2002 Apr 15; 20(4):657-63. PubMed ID: 11910301
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Malmqvist K, Ohman KP, Lind L, Nyström F, Kahan T.
    J Cardiovasc Pharmacol; 2003 Dec 15; 42(6):719-26. PubMed ID: 14639093
    [Abstract] [Full Text] [Related]

  • 7. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL, Park JB, Pu Q.
    J Hypertens; 2002 Jan 15; 20(1):71-8. PubMed ID: 11791028
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
    Nyström F, Malmqvist K, Ohman KP, Kahan T.
    J Hypertens; 2002 Aug 15; 20(8):1527-33. PubMed ID: 12172314
    [Abstract] [Full Text] [Related]

  • 10. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L.
    Am J Hypertens; 2002 May 15; 15(5):389-93. PubMed ID: 12022239
    [Abstract] [Full Text] [Related]

  • 11. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvänen AC, Lind L, Kahan T.
    Am J Hypertens; 2008 Jul 15; 21(7):836-9. PubMed ID: 18464745
    [Abstract] [Full Text] [Related]

  • 12. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Hallberg P, Lind L, Michaëlsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Melhus H.
    J Hypertens; 2003 Mar 15; 21(3):621-4. PubMed ID: 12640257
    [Abstract] [Full Text] [Related]

  • 13. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J, Malmqvist K.
    J Hypertens; 2007 Sep 15; 25(9):1958-66. PubMed ID: 17762662
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
    Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Melhus H.
    J Hypertens; 2002 Oct 15; 20(10):2089-93. PubMed ID: 12359989
    [Abstract] [Full Text] [Related]

  • 16. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A, Bregman B, Agabiti Rosei E, Williams B, Dubourg O, Clairefond P, Brudi P, Gosse P, Guéret P.
    J Hum Hypertens; 1998 Jul 15; 12(7):479-83. PubMed ID: 9702935
    [Abstract] [Full Text] [Related]

  • 17. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
    Müller-Brunotte R, Edner M, Malmqvist K, Kahan T.
    J Hypertens; 2005 Mar 15; 23(3):633-40. PubMed ID: 15716707
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
    Stumpe KO, Haworth D, Hoglund C, Kerwin L, Martin A, Simon T, Masson C, Kassler-Taub K, Osbakken M.
    Blood Press; 1998 Jan 15; 7(1):31-7. PubMed ID: 9551875
    [Abstract] [Full Text] [Related]

  • 19. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
    Liljedahl S, Kahan T, Lind L, Arnlöv J.
    Echocardiography; 2009 Aug 15; 26(7):753-8. PubMed ID: 19486119
    [Abstract] [Full Text] [Related]

  • 20. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
    Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L.
    Am J Hypertens; 2004 Jan 15; 17(1):8-13. PubMed ID: 14700505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.